the 2Department of Microbiology, Hope Hospital, Salford M6 8HD SUMMARY A 73-year-old diabetic presented with septic arthritis of the knee; Pseudomonas aeruginosa was isolated. She was successfully treated with a combination of parenteral and intraarticular ceftazidime, after failure to eradicate the organism with adequate serum levels of gentamicin and full doses of azlocillin.
The patient was treated with intravenous gentamicin and azlocillin 2 g every eight hours, to which the organism was sensitive. Gentamicin was given for two weeks but had to be stopped because of persistently high serum levels secondary to poor renal function. Azlocillin was continued for a total of five weeks, but despite adequate serum bactericidal activity pseudomonas was still being isolated from the joint fluid, and the knee remained hot and swollen. X-ray films at this time showed evidence of bone involvement, with erosion of the medial margin of the right upper tibia. Azlocillin was discontinued, and treatment commenced with ceftazidime, to which the organism was also sensitive, 1-5 g intravenously daily and 100 mg intra-articularly, initially weekly increasing to three times per week. Within two weeks of starting this regimen there was considerable improvement in both the patient's clinical state and that of the infected knee. We continued this treatment for two months, and followed it with one month of intramuscular ceftazidime. At the end of this period the knee showed no signs of continuing infection and was pain free with a good range of movement. Serial joint aspirations were consistent with response to treatment, with a marked fall in the white cell count. There was no evidence of a recurrence of infection when the patient was reviewed six months later. 499 Discussion Septic arthritis due to Gram-negative organisms is still relatively uncommon, but there is evidence that the frequency is increasing.' Intravenous drug use and impaired host defence are the two most important predisposing factors.
Ceftazidime is a third generation cephalosporin, active against pseudomonas species and was then under trial. In this particular patient it was used because intravenous therapy with bactericidal serum levels of gentamicin and azlocillin had failed to eradicate the pseudomonas infection after five weeks, and this situation usually indicates a very 2 poor prognosis.
Experience of treating coexisting septic arthritis and crystal induced arthritis is very limited, as this association has been reported on only 13 occasions, five of which were due to Gram-negative bacilli. '14 Intra-articular antibiotics are rarely given in the treatment of septic arthritis, as the penetration of parenteral and oral antibiotics across the synovial membrane into the synovial fluid is said to be good.157 We believe that this is the first occasion that ceftazidime has been administered intraarticularly, and though we have no evidence that it contributed to the eventual successful outcome, we feel this mode of administration should be seriously considered to supplement parenteral or oral therapy when factors such as coexistent pyrophosphate arthritis are likely to make eradication of infection difficult.
This case also illustrates the importance of synovial fluid culture even when crystals have been shown in an acutely inflamed joint.
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